The tool for the early detection of dementia
Neurosalience® is a tool for the early detection of dementia from structural MRI and CT data, capable of processing even low-resolution MRI data and CT scans.
Neurosalience® is a tool for the early detection of dementia from structural MRI and CT data, capable of processing even low-resolution MRI data and CT scans.
Globally, due to an aging population, it is predicted that the number of patients with dementia will rise to 75 million by 2030.
In the UK, the average cost per patient is over £32,000 a year. The current diagnostic pipeline only allows treatment and lifestyle changes to begin once symptoms have occurred.
75 million patients by 2030
Average cost = £32,000 per patient
Existing screening methods:
- Lack sensitivity
- Are not automated enough
- Detect existing symptoms
At Neurosalience, we develop a tool for the early detection of dementia from structural MRI scans. The tool is the first in the world capable of assessing the risk of dementia even on low-resolution MRI data and is extendable for use with CT data.
Early detection of the risk of dementia helps reduce long-term patient-related care costs and improves quality of life, as there are scientifically proven lifestyle changes that can slow the progression of the disease.
We use interpretable machine learning algorithms to assess brain aging.
view our technology
We are open to collaboration and partnerships with hospitals, MedTech, and pharmaceutical companies. Contact us to arrange a demo of our product!
